3 results
Primary: to assess the effect of intravenous (IV) ozanezumab (15 mg/kg once every 2 weeks) compared to placebo on the physical function and survival of ALS patients over a treatment period of 48-weeks.Secondary (major): other clinical outcomes,…
The primary objective of this study is:• To evaluate the non-inferiority of switching to a TAF Containing STR relative to maintaining TDF Containing Regimens in Virologically Suppressed HIV-1 positive subjects as determined by having HIV 1 RNA * 50…
The primary objective of this study is:• To evaluate the efficacy of a single-tablet regimen (STR) containingelvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) versus a STRcontaining elvitegravir/cobicistat/emtricitabine/…